International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.
International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.
Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.
Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.
Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.
Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.
Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.
International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.
Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.
Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.
Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.
An International Open Access Journal Devoted to General Medicine.
Exp Ther Med 11: [Related article:] 49-56, 2016; DOI: 10.3892/etm.2015.2860
Subsequently to the publication of the above article, an interested reader drew to our attention that the article describes the use of the drug acetazolamide for IgA nephropathy on a number of occasions in the text, whereas the references refer to the drug azathioprine. The authors have confirmed that, owing to an oversight on their part, all the references to “acetazolamide” in their paper (abbreviated as ‘AZA’) should have been written as “azathioprine” (first, in the Abstract on p. 49, line 18, and subsequently in the legends of Table I and Figs. 2 and 7). Given the serious nature of this error, please note that the drug name for ‘AZA’ has been corrected in the article itself, and an updated version of the paper has been uploaded to PubMed Central. Furthermore, the abbreviation for leflunomide should have been written throughout the paper as “LEF”, not as “LET”.
The authors deeply regret that these errors were allowed to enter into their text, and were not corrected prior to publication. The authors also apologize to the readership for any inconvenience caused.